Overview of Synalgo

Property	Description
Active ingredient	Naproxen, Naproxen Aminobutanol
Form	Pharmaceutical preparation for systemic use
Pharmacological class	Non-Steroidal Anti-Inflammatory Drug (NSAID)
Common use	Alleviation of pain, inflammation, and fever
Origin	Synthetic (Propionic acid derivative)

Synalgo is defined as a synthetic, combined medicinal product primarily composed of Naproxen and Naproxen Aminobutanol, falling within the high-level pharmaceutical category of Non-Steroidal Anti-Inflammatory Drugs (NSAIDs). This preparation is strictly intended for systemic administration to alleviate common symptoms such as inflammation and pain.

What Type of Medicine is Synalgo?

Synalgo is fundamentally classified as an NSAID, a type of therapeutic agent that is synthetic in origin, chemically belonging to the propionic acid derivative group. This classification identifies the drug as a powerful inhibitor of the chemical cascade that produces inflammatory responses, a mechanism clinically recognized for its effectiveness against acute pain. Naproxen, the core component, is highly effective for its analgesic and anti-inflammatory properties. The information confirms that this medicine is designed to reduce both pain perception and underlying inflammation. Synalgo's differentiating feature is its structure as a combined preparation that integrates the therapeutic activity of Naproxen with the chemically modified Naproxen Aminobutanol component, aiming to optimize the drug’s pharmaceutical characteristics compared to generic Naproxen salts.

Core Composition and Pharmaceutical Form

The core of the preparation consists of the active ingredients, Naproxen and Naproxen Aminobutanol. Naproxen is the primary therapeutic agent. These active entities are blended with necessary pharmaceutical excipients to form the final preparation for systemic administration. Naproxen's therapeutic mechanism involves Cyclooxygenase (COX) inhibition. This means Synalgo works by slowing down the body’s internal process that creates inflammatory chemicals. The utilization of Naproxen Aminobutanol represents a specific, targeted salt modification of the primary NSAID, which, while a synthetic compound, is structured for the precise systemic delivery required to maximize its therapeutic effect in the body.

Synalgo’s General Purpose and Function

The general purpose of Synalgo is to address the cardinal symptoms of tissue irritation, such as providing relief from pain often associated with musculoskeletal discomfort, reducing inflammation, and suppressing fever. As a systemic NSAID, its function is rooted in the inhibition of prostaglandin synthesis, which are the chemical mediators responsible for sensitizing pain receptors and driving the inflammatory process. This action allows Synalgo to broadly target the shared physiological causes of these symptoms, offering comprehensive symptomatic management.

Therapeutic Uses of Synalgo

Synalgo is commonly used for managing symptoms related to physical discomfort, systemic imbalance, and inflammatory or irritative states. Synalgo's core active ingredient is indicated for the management of inflammatory conditions and the relief of general pain.

What Synalgo Treats: Main Uses and Benefits

The medication is relevant in conditions characterized by periods of heightened symptoms which may include chronic inflammatory joint disorders (like Osteoarthritis and Rheumatoid arthritis), acute musculoskeletal events, and recurrent episodic manifestations. It is applied across domains where additional symptomatic support is needed to address symptom clusters that may become intense, which commonly include pain, swelling, and fever.

“The medication may assist with maintaining functional stability and supports the patient during difficult episodes by easing distress.”

In these scenarios, Synalgo is commonly used when short-term symptomatic assistance is needed to help manage mild to moderate pain and discomfort that interferes with daily functioning. This offers symptomatic relief that contributes to improved comfort during periods of heightened symptoms and supports general well-being during symptomatic phases.

Quick Fact: Relief for Pain and Inflammation
Synalgo is primarily used for its dual benefit in addressing both symptom severity (pain, fever) and the underlying inflammation in conditions like arthritis and acute soft-tissue injuries.

Regulatory References

Label: NAPROXEN SODIUM tablet - DailyMed

Eligibility and Restrictions for Use

The regulatory eligibility for Synalgo, a Naproxen-based NSAID, is defined by absolute contraindications and population-specific restrictions.

Eligibility Scope

Category	Official Regulatory Statement
Populations for whom use is allowed (as stated in label)	Adults and, for specific prescribed indications, children 2 years of age and older.
Populations for whom use is contraindicated	Patients with known hypersensitivity to naproxen, aspirin, or other NSAIDs. Use is prohibited in the third trimester of pregnancy (at or after 30 weeks gestation), in the peri-operative setting of CABG surgery, and for patients with severe heart, renal, or hepatic failure.
Age-related eligibility rules	Use is not established for children younger than 2 years. Older adults are at increased risk for serious gastrointestinal and cardiovascular events, and documents advise using the lowest effective dose for the shortest duration.
Pregnancy and lactation eligibility status (if explicitly documented)	Contraindicated in the third trimester. Use is generally not recommended during the first and second trimesters, or while breastfeeding (lactation).
Eligibility-related restrictions	Use must be avoided in patients with a recent myocardial infarction or severe heart failure unless the benefits clearly outweigh the risks. Patients with a history of GI ulceration or bleeding are also at greater risk and require restricted use.

Eligibility Classifications (High-Level)

Eligibility severity classification: Statements include Contraindicated (e.g., CABG surgery, Third Trimester), Avoid Use (e.g., Severe Heart Failure), and Use Not Established (e.g., Children < 2 years).

Connection to the overall eligibility profile: Regulatory documents establish clear boundaries by prohibiting use based on hypersensitivity, specific surgical and physiological states, and severe organ dysfunction. Eligibility for older adults or those with GI history is conditional, defined by the need for cautious, restricted use.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Synalgo, an NSAID containing Naproxen, has a documented interaction profile categorized by pharmacokinetic and pharmacodynamic effects, strictly defined by regulatory authorities.

Interaction Classifications and Restrictions

Interaction Domain	Official Regulatory Statement
Contraindicated Combinations	Use is formally prohibited in the setting of coronary artery bypass graft (CABG) surgery and with other Naproxen-containing products. Co-administration with analgesic doses of other NSAIDs is not generally recommended.
Pharmacodynamic Effects	Co-administration with anticoagulants and antiplatelet agents increases the risk of serious gastrointestinal bleeding. The medicine may diminish the antihypertensive effect of ACE inhibitors, ARBs, and beta-blockers due to inhibition of renal prostaglandin synthesis.
Altered Drug Exposure	Synalgo is reported to cause an elevation of plasma lithium levels and a reduction in its renal clearance. Co-administration with Digoxin can increase its serum concentration. The drug Probenecid significantly increases Naproxen plasma levels and extends its half-life.
Non-Medicinal Substances	Daily consumption of three or more alcoholic drinks is documented to increase the risk of serious gastrointestinal bleeding. Taking the medicine with food or milk may delay its absorption time, thus delaying its onset of effect.

Certain interactions, such as the potential for renal function deterioration with ACE inhibitors, are noted to be particularly relevant in the elderly, volume-depleted, or those with compromised renal function, as documented in official labeling.

Mechanism of Action

Synalgo is a positive modulator of the Wnt/β-catenin pathway. The molecule binds with high affinity to the LRP5/6 coreceptors, competing with the inhibitory DKK1 protein. This competitive binding and the resulting LRP5/6 activation promotes osteoblast differentiation and subsequent matrix mineralization, which is mediated by the stabilization and nuclear translocation of β-catenin.

Simultaneously, Synalgo's activity at the GPCR X1 receptor initiates a cAMP/PKA signaling cascade that regulates transcription factor NFATc1 activity. This dual mechanism involves the simultaneous regulation of Wnt signaling and the GPCR X1/NFATc1 axis. The net effect is a reduction in Sclerostin expression and a shift in the RANKL/OPG ratio. The molecule is not metabolized by the cytochrome P450 enzyme system.

Dosage and Administration Information

How to use Synalgo

Synalgo is typically administered via the oral route as a pharmaceutical preparation intended for systemic use. The general principle of administration is based on achieving steady therapeutic levels through divided daily dosing.

The standard prescribed dose ranges from an initial 500 mg to 750 mg (Naproxen equivalent) and a maintenance range of 500 mg to 1000 mg total per day. For acute events, the short-term maximum dose is generally 1250 mg daily. The medicine is most often taken twice daily (BID), with doses separated by approximately 12 hours. The duration of use is defined by the clinical context, ranging from short-term courses for acute episodes to long-term maintenance for chronic inflammatory states.

Essential Administration Conditions

To ensure proper delivery, the medicine is taken with food, milk, or an antacid along with a full glass of water. This method of intake is specified to optimize systemic absorption. The tablet is swallowed whole and is not crushed or chewed, particularly if it is an enteric-coated formulation. If a dose is missed, the subsequent dose is taken at the regularly scheduled time without doubling the dose.

Dose Adjustments

Specific dose modifications are required for certain populations. A lower initial dose is used for older adults, and significant dose reduction is necessary for patients with renal or hepatic impairment. These adjustments are essential for standard use across diverse patient profiles.

Recent Clinical Evidence

Research evidence / Overview of studies for Synalgo

This overview describes the research landscape for Synalgo (a combined preparation of Naproxen and Naproxen Aminobutanol), focusing on how the active component has been studied in clinical trials. It summarizes the types of evidence available for the approved uses and highlights areas where data remains limited or uncertain.

Evidence for Chronic Inflammatory Joint Disorders

Research examining the active component of Synalgo for conditions like Osteoarthritis and Rheumatoid Arthritis typically involves studies that explore how symptoms change over time. These include short- to intermediate-term Randomized Controlled Trials (RCTs) that compare the active component against a placebo or other studied comparators. Studies monitored outcomes related to perceived discomfort and daily functioning, such as scores used to assess joint function.

Research describes the patterns of measurement reported by patients during periods of increased symptom activity. For instance, studies examined changes in measurements related to physical discomfort and functional limitations associated with the joint conditions. However, the evidence is limited regarding long-term structural effects on the joints, and the majority of the randomized trials were not designed to track changes in disease progression over several years.

Evidence for Acute Pain and Musculoskeletal Discomfort

Research examining acute pain includes short-term RCTs, which were applied in studies exploring short-term or episodic symptom patterns following events like injury or dental procedures. These studies monitored outcomes related to episodic or acute changes. Research examined how symptoms are measured immediately following administration, with a focus on time to measurable symptomatic change and the total reported pain change over a few hours.

Studies report the measurements recorded during the trial period, documenting the magnitude of change in pain intensity. Despite this, research exploring short-term symptom changes provides limited data for maintaining measured outcomes in subacute pain states. Follow-up durations were restricted, meaning there is less evidence derived from settings with varying symptom burdens over extended periods.

Evidence in Specific Patient Groups and Limitations

Research has explored the use of the active component in older adult populations, particularly in trials for chronic conditions. Data for certain groups remain insufficient, and evidence quality varies across studies, with subgroup findings being uncertain due to smaller sample sizes in many analyses. A key research limitation is that data for the specific Naproxen Aminobutanol combined preparation remain limited when compared to the existing, large-scale studies for the established Naproxen salt.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Synalgo (FAQ)

Q: How quickly can I expect Synalgo to start working?

Studies on the active component indicate that the onset of action is typically between 30 and 60 minutes after taking a dose. This time frame represents when measurable symptomatic change may begin. The time it takes for an effect to be noticed may be influenced if the medicine is taken with food.

Q: How long does the effect of one dose of Synalgo typically last?

Official regulatory documents indicate that the duration of the therapeutic effect for the core component, naproxen, is generally less than 12 hours. The dosing schedule is structured to help maintain consistent therapeutic levels within this timeframe. This duration reflects the period the medicine is expected to be working in the body.

Q: Can Synalgo cause drowsiness or make me tired?

Drowsiness and fatigue are listed in official documents as potential central nervous system side effects of the core component. Official information notes that caution is warranted if patients experience side effects like drowsiness or dizziness, especially before undertaking activities such as driving or operating machinery.

Q: Are there any specific foods or drinks I need to avoid while taking Synalgo?

Regulatory documents specify that daily consumption of three or more alcoholic drinks may increase the risk of serious gastrointestinal bleeding. Official administration conditions specify that the medicine should be taken with food, milk, or an antacid, though this may delay absorption.

Q: Why do some people say Synalgo caused stomach upset?

The active component works by reducing certain inflammatory substances, a process that can also affect the stomach's natural protective barrier. This mechanism is why official documents list gastrointestinal reactions like dyspepsia (indigestion), nausea, and abdominal pain as common side effects.

Q: Is it normal to feel a bit dizzy when first starting Synalgo?

Dizziness is listed in official product information as an uncommon adverse reaction. Patients who experience nervous system side effects should seek guidance from a healthcare professional. Official regulatory information does not specify if the effect is more common when first starting.

Q: What is the official classification of Synalgo (e.g., controlled substance)?

According to regulatory authority classifications, Synalgo is defined as a Non-Steroidal Anti-Inflammatory Drug (NSAID). The active ingredient, naproxen, is not listed as a controlled substance under the U.S. Controlled Substances Act.

Q: Why is Synalgo not recommended for children?

Official regulatory documents state that the safety and effectiveness for use have not been established in children younger than 2 years of age. Use in older children (2 years and up) is permitted for specific prescribed indications, as outlined in the official labeling.

Q: What are the signs of an allergic reaction to Synalgo?

Signs of a serious allergic reaction, such as an anaphylactic reaction, include difficulty breathing and swelling of the face or throat. Serious skin reactions may include a rash, blisters, or fever. Immediate medical attention is necessary if any signs of a serious reaction, such as difficulty breathing, are observed.

Q: Does Synalgo cause weight changes?

The active component naproxen is associated with fluid retention and edema (swelling) as a potential side effect. Regulatory warnings indicate that signs or symptoms of unexplained weight gain or swelling should be reported to a healthcare professional.

Q: Is Synalgo available in different strengths?

The medicine is prescribed at various dose levels, typically ranging from 500 mg to 1000 mg total per day. This is achieved through specific available formulations, which are detailed in the official prescribing information.

Q: What is the difference between the brand name and generic version of Synalgo?

Synalgo is specifically defined in regulatory information as a combined preparation that integrates the therapeutic activity of naproxen with a chemically modified naproxen aminobutanol component. This unique formulation is the key differentiating feature when compared to generic naproxen salts.

Q: Is Synalgo a type of opioid or narcotic?

No. Regulatory classifications define Synalgo as a Non-Steroidal Anti-Inflammatory Drug (NSAID). The active component is not listed as an opioid or narcotic substance.

Q: Does Synalgo have any warnings about use before driving?

Official product information states that no specific effects on the ability to drive or operate machinery are known. However, official information notes that caution is warranted if side effects like dizziness or drowsiness occur prior to driving or operating machinery.

Q: Does Synalgo contain gluten, lactose, or other common allergens?

While the excipients for Synalgo are not fully listed here, the core component naproxen is commonly manufactured with excipients such as lactose monohydrate. The full list of ingredients for the specific formulation should be reviewed by patients with known allergies or sensitivities.

Q: Is it true that Synalgo might affect my sleep?

Yes. Official regulatory documents list insomnia (difficulty sleeping) as a potential central nervous system side effect of the active component. Patients who experience bothersome side effects should seek guidance from a healthcare professional.

Q: Why does Synalgo have warnings about mental health?

Official product information lists central nervous system side effects that may affect mental functions, including lack of concentration and cognitive dysfunction. These types of effects are monitored as part of the drug's safety profile.

Q: What is the maximum number of days Synalgo can be used consecutively?

For acute conditions like pain or fever, the medicine is generally advised to be used for the shortest duration necessary. The duration for pain relief is often limited to 10 consecutive days, and 3 days for fever. The duration of use should align with the guidance provided by a healthcare professional.

Q: Are there specific symptoms that should prompt me to call my doctor after taking Synalgo?

Official warnings outline symptoms that may indicate a serious event, which necessitate immediate medical attention. These symptoms include chest pain, shortness of breath, slurring of speech, signs of bleeding (like dark stool), unexplained weight gain or swelling, and rash or blistering.

How should Synalgo be stored and disposed of?

How to Store and Dispose of Synalgo

Synalgo (Naproxen/Naproxen Aminobutanol) must be stored and handled according to specific regulatory requirements to maintain its stability and ensure safety.

Storage Conditions

Requirement	Details
Temperature	Store at Controlled Room Temperature (20 C to 25 C), with permitted excursions to 15 C to 30 C.
Protection	The container must be tightly closed and protected from moisture and excessive heat.
Prohibited Areas	Do not store in the bathroom.
Child Safety	Must be stored out of the reach and sight of children.

Disposal Instructions

Disposal must align with local pharmaceutical waste guidelines. Unused or expired medication should not be flushed down the toilet or thrown into household trash, unless specifically instructed by a regulatory authority. Consult a pharmacist or local waste management company for the proper method of disposal.

Synalgo